Bobak Mortazavi is an Associate Professor in the Department of Computer Science & Engineering at Texas A&M University. His research focuses on medical analytics, machine learning, wearable sensors, and cyber-physical systems. He leads interdisciplinary projects in healthcare technology, including AI-driven diagnostics and predictive modeling for cardiovascular diseases. He has received notable awards such as the Best Demonstration Award at IEEE EMBS 2012 and the Best Paper Award at the Fourth International Conference on Data Analytics 2015. His work bridges machine learning with clinical applications, emphasizing practical solutions for healthcare challenges. Recent research includes developing AI tools for aortic stenosis detection, electrolyte estimation via ECG, and real-time patient monitoring systems. He collaborates with industry and academic partners to advance telemedicine and wearable health technologies. Key contributions include the SMART-LV project for smartphone-based cardiac diagnostics and the ArterialNet framework for blood pressure reconstruction using wearable sensors. His work is published in top journals like IEEE Journal of Biomedical and Health Informatics and Elsevier's Pervasive and Mobile Computing.
Prof. Dr. Dennis Säring is a faculty member at the University of Applied Sciences Wedel , specifically affiliated with the School of Engineering. His academic and research activities focus on Deep Learning , Medical Image Analysis , and applications of Artificial Intelligence in healthcare and biomedical imaging. He has led seminars on Deep Learning topics and supervised student projects in Autonomous Driving at Audi's AADC 2018 competition. Research Highlights : Cardiovascular imaging, forensic age estimation via MRI, neural network-based bone segmentation, and cerebrovascular aneurysm analysis. Technical Expertise : Cardiac MRI, 3D/4D image processing, parametric mapping, and spatiotemporal data fusion. His recent publications (2018-2023) emphasize 3D MR segmentation for age assessment, CMR strain analysis in athletes, and T1/T2 mapping for myocarditis. Key collaborations include institutions like the University Medical Center Hamburg-Eppendorf and Wedler Hochschulbund, with funding for autonomous vehicle research. While no explicit scientific awards are listed, his work spans clinical cardiology, forensic radiology, and AI-driven medical diagnostics.
Dr. Ahmed Mahrous Abouzaid is an Adjunct Professor affiliated with the School of Cardiovascular & Metabolic Health at the University of Glasgow . His research focuses on cardiovascular disease, particularly angina management, myocardial infarction pathophysiology, and clinical trial methodologies. He specializes in advanced diagnostic techniques like electrocardiography stress testing, cardiovascular magnetic resonance (CMR), and fractional flow reserve (FFR) analysis. His work emphasizes translating clinical research into improved patient outcomes, with a focus on non-obstructive coronary artery disease, left ventricular remodeling, and optimizing treatment strategies for non-ST elevation myocardial infarction (NSTEMI). He has contributed to high-impact studies published in journals such as European Heart Journal and Circulation . Recent research highlights include a 2024 randomized controlled trial evaluating invasive endotyping in angina patients and a 2025 study on electrocardiography stress testing for diagnostic accuracy. While no awards are explicitly listed, his publications reflect a strong commitment to advancing cardiovascular diagnostics and clinical practice. No grants or advising details are provided in the available text. His affiliation suggests active participation in collaborative research within the School's cardiovascular health initiatives.
Dr. Jose Perdomo is a Research Fellow at the Central Clinical School, Sydney Medical School, within the Faculty of Medicine and Health at the University of Sydney. He is based at the Charles Perkins Centre, where his research focuses on endothelial damage, immune complex-driven thrombosis, and platelet formation mechanisms. His work employs techniques such as flow cytometry, microfluidics, and intravital microscopy. Dr. Perdomo holds a PhD from the University of Sydney’s School of Molecular and Microbial Biosciences and received a Vice-Chancellor’s Fellowship. His research has led to two international patents and recognition, including 1st prize in the 2020 China Shenzhen Innovation Competition. His studies explore targeted inhibitors to prevent immune complex formation and thrombosis, with applications in cardiovascular health. His research interests include the interplay between white blood cells, endothelial cells, and platelets, with a focus on desialylation, apoptosis, and NETosis in immune thrombocytopenia. He has contributed to understanding vaccine-induced immune thrombocytopenia and thrombotic complications post-myocardial infarction. His findings have been featured in Nature Communications , Blood Advances , and other high-impact journals. Awards: 1st prize in China Shenzhen Innovation Competition (2020). Labs/Teams: Charles Perkins Centre, University of Sydney. Grants: Vice-Chancellor’s Fellowship (University of Sydney). Media Contributions: Insights into AstraZeneca vaccine-related blood clots featured in The Guardian , SMH , and ABC News.
Ahmed Hassoon is an Assistant Research Professor at the Johns Hopkins Bloomberg School of Public Health, with a primary appointment in the Department of Epidemiology and joint appointments in the Department of Neurology at the School of Medicine and the School of Engineering. He is affiliated with several key research centers, including the Welch Center for Prevention, Epidemiology and Clinical Research, the Center for Diagnostic Excellence, and the Center for Humanitarian Health. MPH, Johns Hopkins Bloomberg School of Public Health, 2014 MD, Baghdad College of Medicine, 2004 Dr. Hassoon’s research is centered on leveraging data science and artificial intelligence to improve healthcare quality and safety, particularly in diagnostic accuracy. His work spans applications in lung cancer, stroke, and emergency medicine, with a strong emphasis on reducing diagnostic errors using frameworks like symptom-disease pair analysis (SPADE). He is deeply engaged in developing AI models that reason across multiple clinical modalities to enhance patient outcomes. His recent publications highlight a strong trend in diagnostic safety, AI-driven interventions, and epidemiological analysis of misdiagnosis harms. Key themes include the validation of computable phenotypes, measurement of diagnostic error burden, and the impact of mental health on acute care diagnostics. Hubert Humphrey Fellowship Award, U.S. Department of State (2010) US President Appreciation Certificate, The White House (2011) Atlas Corps Award (2012) Sommer Scholarship Award (2013) State of Maryland Cigarette Restitution Fund Faculty and Translational Research Awards (2016–2017) Institute for Healthcare Improvement (IHI) Fellowship (2024) Dr. Hassoon is a recipient of the AHRQ K08 Career Development Award focused on improving cancer diagnostic safety at Johns Hopkins Hospital. He co-instructs graduate-level courses in data science and AI with Professor Brian Caffo, contributing to the training of the next generation of public health data scientists. He has not formally advised students listed in the provided texts. His collaborative research spans multiple institutions and has been widely disseminated through policy, news, and social media, indicating significant real-world impact. His work is deeply integrated with the Welch Center and the Center for Diagnostic Excellence, where he contributes to translational research initiatives aimed at improving clinical decision-making and patient safety through innovative data-driven approaches.
Hsueh-Chia Chang is the Bayer Professor of Chemical Engineering in the Department of Chemical and Biomolecular Engineering at the University of Notre Dame's College of Engineering. He also holds a concurrent faculty position in the Department of Aerospace and Mechanical Engineering. As Principal Investigator of the Chang Lab, he leads cutting-edge research in microfluidic and nanofluidic technologies for biomedical applications. Prof. Chang received his B.S. in Chemical Engineering from Caltech in 1976, followed by M.S. and Ph.D. degrees in Chemical Engineering from Princeton University in 1977 and 1980, respectively. His academic journey has established him as a leader in the field of microfluidics and biosensing technologies. Chang's research focuses on developing low-cost liquid biopsy nanotechnologies for cancer screening and therapy management. His lab specializes in microfluidic and nanofluidic research coupled with electrokinetics, optics, plasmonics and acoustics for biosensing applications. Key research areas include Electrokinetics & Biosensing, Optics & Plasmonics, Nanoelectrokinetics, and Droplet Microfluidics. The Chang Lab has developed innovative platforms that can isolate and sort tumor cells, exosomes, microvesicles, lipoproteins, and stress granules from blood samples, then lyse these structures to release RNA/protein biomarkers for detection and quantification. His recent publications reveal a strong focus on extracellular vesicle diagnostics, cancer biomarker detection, and point-of-care diagnostic technologies. The research spans multiple disciplines including oncology, cardiology, and neurology, with applications for pancreatic, liver, breast, ovarian, and lung cancers as well as myocardial infarction diagnosis. Fellow of American Institute of Medical and Biological Engineering (2025) Provost Research Achievement Award, Notre Dame (2024) Fellow of the National Academy of Inventors (2020) Lifetime Achievement Award, American Electrophoresis Society (2019) Fellow of the American Physical Society (1997) Presidential Young Investigator Award, NSF (1985) Prof. Chang has advised over 50 PhD students and postdocs who have gone on to prominent positions in academia and industry. His lab has secured significant funding and has commercialized several technologies through startups like Aopia Biosciences, which launched NanoEx at ISEV 2024. The Chang Lab maintains active collaborations with medical researchers for validating their diagnostic platforms against various cancers and cardiac conditions.
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Dr. Nivee Pradip Amin serves as Clinical Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian Hospital, holding leadership roles as Associate Director for Consultative Cardiology and Director of the Women's Heart Program & Preventive Cardiology. Her clinical expertise spans general cardiology, preventive cardiology, and echocardiography with focus on high-risk cardiovascular prevention. Her educational credentials include: B.A., B.S. in International Studies and Business from University of Pennsylvania (2002) M.D. from Johns Hopkins University School of Medicine (2007) M.H.S. in Clinical Investigation from Johns Hopkins Bloomberg School of Public Health (2013) Research centers on sex-based disparities in cardiovascular outcomes, women's heart health across the lifespan, and preventive strategies for coronary/valvular disease. She investigates intersections between cardiology and obstetrics/oncology, emphasizing personalized risk assessment and early intervention to improve quality of life. Analysis of her publications reveals consistent focus on women's cardiovascular biomarkers (e.g., breast arterial calcium), obstetric complications as long-term risk factors, and disparities in revascularization outcomes. Her work leverages large-scale database analysis to address gaps in preventive care for high-risk populations including cancer patients and those with cirrhosis. Dr. Amin maintains active board certifications in Internal Medicine, Cardiovascular Diseases, Nuclear Cardiology, and Echocardiography through the American Board of Internal Medicine, and holds professional memberships in the American College of Cardiology, American Society for Preventive Cardiology, and American Heart Association. She provides inpatient consultative care on cardiac telemetry units while leading the Women's Heart Program, which integrates preventive cardiology services with gender-specific treatment protocols. Fluent in Spanish, she emphasizes culturally competent care tailored to individual patient needs across diverse populations.
Elvin Kedhi, MD, PhD is an Investigator at the Research Institute of the McGill University Health Centre (RI-MUHC) at the Glen site, where he is affiliated with the Cardiovascular Health Across the Lifespan Program. As a faculty member at McGill University's Faculty of Medicine, he contributes to both clinical practice and academic research in cardiology. Dr. Kedhi's research focuses on interventional cardiology, particularly coronary artery disease management, fractional flow reserve techniques, and clinical trials comparing different treatment approaches for cardiovascular conditions. His work often involves complex clinical scenarios including patients with diabetes, high bleeding risk, and multivessel coronary disease. He has pioneered research on thin-cap fibroatheroma identification and its clinical implications, as well as optimal dual antiplatelet therapy durations following stent implantation. His recent publications demonstrate a strong emphasis on comparing transcatheter and surgical approaches for treating patients with combined aortic valve stenosis and coronary artery disease. Dr. Kedhi frequently collaborates with international research teams across Europe and North America, contributing to large-scale multicenter clinical trials that shape current cardiovascular treatment guidelines. Active researcher in interventional cardiology clinical trials Focus on optimizing treatment strategies for complex coronary artery disease Expertise in fractional flow reserve and intravascular imaging techniques International collaborations across multiple continents Dr. Kedhi maintains an active clinical research program with numerous ongoing studies examining innovative approaches to cardiovascular disease management. His work bridges the gap between technological advances in cardiac interventions and practical clinical applications that improve patient outcomes.
Amy Catherine Rowat is a full Professor in the Department of Integrative Biology and Physiology at UCLA's College of Letters and Science. She directs an interdisciplinary research program that integrates mechanobiology, microfluidics, cancer biophysics and food engineering to understand how physical forces shape cell behavior and to develop sustainable biotechnologies. Education & Affiliations: Professor, Department of Integrative Biology and Physiology, UCLA Member, UCLA College of Letters and Science Research Interests: Rowat's group deciphers how mechanical properties of cells and their nuclei influence disease progression and therapeutic response. Using high-throughput microfluidic deformability cytometry, her team discovered that cancer cells become stiffer and more invasive upon β-adrenergic signaling, linking stress hormones to metastatic potential. Parallel efforts focus on nuclear envelope mechanics, showing that histone H1.0 and transient nuclear deformation modulate chromatin structure and cell reprogramming. Beyond biomedicine, Rowat pioneers biophysical approaches for sustainable food production. She engineers edible scaffolds and emulsion-templated microcarriers to culture meat at scale, demonstrating spontaneous fusion of adipogenic and myogenic microtissues into marbled steak-like constructs. Recent Article Trends (2020-2025): Her latest publications reveal a cohesive trajectory: coupling mechanobiology to epigenetic regulation (viscoelastic matrix enhances chromatin remodeling), advancing single-cell mechanical phenotyping (optomagnetic arrays, high-throughput screens), translating findings to cancer therapy (β-blockers to sensitize chemotherapy) and expanding engineered foods (scalable cultured-meat bioprocessing). Funding & Awards: NIH R21 CA245667 (PI) – Repurposing beta-blockers to improve chemotherapy response (2021-2023) Laboratory & Teams: Rowat leads an active research laboratory at UCLA that trains graduate students and postdocs at the intersection of physics, engineering and biology. The lab maintains collaborations across UCLA Engineering, Jonsson Comprehensive Cancer Center, and external partners in food science and biotechnology companies.
Dr. Xin Zhou is an Oxford-Bristol Myers Squibb Fellow at the Department of Computer Science, University of Oxford. Her research integrates computational modeling, clinical data, and experimental findings to investigate cardiac disease mechanisms and develop human-based simulations for drug evaluation. BSc and MSc in Life Sciences, Beijing Normal University DPhil in Computational Biology, University of Oxford Her work focuses on multi-scale cardiac modeling , particularly in ischemic heart disease and heart failure, exploring ionic currents, tissue conduction, and organ-level dynamics. She develops electromechanical simulations to study cardiac alternans and arrhythmic risks, translating these into clinical applications for patient stratification and pharmaceutical testing. Recent publications emphasize in silico clinical trials , sex-specific cardiometabolic analysis, and Purkinje network modeling. Collaborative efforts with clinicians and pharmaceutical partners highlight her translational approach to regulatory science. Model of the Year 2024, BioModels EPSRC Impact Acceleration Account Microsoft Research Project Award Recognition Award, University of Oxford She supervises PhD and MSc students in computational cardiology, while serving on the editorial board of Frontiers in Physiology . Her current projects involve digital twinning and predictive cardiac safety models to reduce animal testing reliance.
Molly Maleckar is a Research Professor at the Computational Physiology Department of Simula Research Laboratory , Oslo, Norway. Her work bridges computational modeling, cardiac electrophysiology, and biomedical applications, with a focus on arrhythmia mechanisms, fibrosis modeling, and machine learning integration in cardiac risk prediction. Research Interests include: Computational Cardiology Ion Channel Dynamics Machine Learning in Medicine Excitable Tissue Modeling Cardiac Fibrosis Analysis Biomedical Simulation Scientific Contributions span 15+ publications (2018-2024) addressing atrial fibrillation, calcium handling, and AI-driven ECG analysis. Key collaborative projects involve patient-specific ventricular modeling and educational initiatives like the Simula Summer School in Computational Physiology .
Dr. Parth Chansoria is a Lecturer at the Department of Health Sciences and Technology at ETH Zürich, where he leads biofabrication research within the Tissue Engineering and Biofabrication (TEB) group. His work focuses on structured light technology for regenerative medicine applications, including in vivo bioprinting and microgravity-based tissue engineering. He holds Ambizione and Spark grants from the Swiss National Science Foundation and has pioneered innovations in light-guided biofabrication, collagen-based resins, and anisotropic tissue design. Research domains include: Filamented light biofabrication for aligned tissues Minimally invasive light-based in vivo bioprinting Musculoskeletal tissue engineering in microgravity Isotonic collagen-based photocrosslinkable resins He has secured over 6 patents and received prestigious awards including the ISBF Early Career Investigator Award (2022), Marie Curie Actions Fellowship (2021), and SME 30 Under 30 recognition (2021). His interdisciplinary research bridges bioengineering, materials science, and clinical applications. Key collaborations include projects at UNC Chapel Hill (USA) and NC State (USA), where he developed biomimetic patches for dynamic organ pathologies and ultrasound-assisted cell patterning. His lab explores novel bioinks, hybrid fabrication techniques, and translational applications in regenerative medicine.
Steff Lewis is a Professor of Medical Statistics at the University of Edinburgh , affiliated with the Usher Institute within the College of Medicine and Veterinary Medicine . She leads the statistics group at the Edinburgh Clinical Trials Unit and holds roles in the Deanery of Molecular, Genetic and Population Health Sciences . Her expertise spans meta-analysis, randomized trial design, and clinical trial governance, with involvement in Cochrane Collaboration and UK Clinical Research Collaboration initiatives. Education: MSc and PhD in Medical Statistics. Research Interests: Focuses on methodological advancements in clinical trial reporting (e.g., CONSORT and SPIRIT guidelines), cardiovascular outcomes (e.g., SCOT-HEART trial), stroke prevention (ASPIRING trial), and ethical data management. She actively contributes to international standards for trial protocols, anonymization practices, and statistical validation. Recent Contributions: Over 200 peer-reviewed articles and 37 ongoing projects, including leadership in trials assessing antiplatelet therapies, Paget’s disease interventions, and pediatric asthma treatments. Collaborates globally on guidelines for randomized trials and data-sharing protocols. Grants & Teams: Principal or co-investigator on projects funded by NIHR, BHF, and ESRC, including trials on iron therapy in critical care (INTACT-2) and cannabinoid treatments for endometriosis pain (ENDO-CAN). Leads multidisciplinary teams integrating statistical rigor with clinical innovation. Labs/Teams: Embedded within the Edinburgh Clinical Trials Unit and the Centre for Population Health Sciences , fostering collaborative research across molecular, genetic, and public health domains.
Charless Fowlkes is a Professor in the Department of Computer Science at the University of California, Irvine (UCI). His research focuses on computational vision, spanning human visual system understanding, machine vision systems, and applications in biomedical informatics and forensic science. He holds a Ph.D. from UC Berkeley (2005). His work integrates techniques from computer vision, AI, and applied mathematics to address challenges in automated biological data analysis, morphology, and spatial gene expression. Key research areas include forensic science (e.g., shoeprint matching via 3D reconstruction), biomedical applications (e.g., heart function mapping and pollen classification), and AI-driven systems for scene understanding. Recent projects include a $20M forensic science center funded by the National Institute of Justice. His publications emphasize geometric reasoning, 3D reconstruction, and adaptive learning algorithms. Notable contributions include developing algorithms for 3D human pose estimation with scene constraints, automated pollen identification via CNNs, and frameworks for cross-domain forensic analysis. His work bridges theoretical computer vision with real-world applications in forensics, healthcare, and environmental science.
